El-Shal Amal S, Zidan Haidy E, Rashad Nearmeen M
Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt,
Mol Biol Rep. 2014;41(4):2287-98. doi: 10.1007/s11033-014-3082-0. Epub 2014 Jan 28.
Recently, several reports addressed the associations of adiponectin (ADIPOQ) gene polymorphisms with abnormal adiponectin serum levels, type 2 diabetes mellitus (T2DM), and diabetic nephropathy (DN); however, results are inconsistent. This study aimed to investigate the possible association of ADIPOQ gene polymorphisms with T2DM and/or DN and whether they affect serum adiponectin levels in Egyptian population. Two hundred and ninety-six T2DM patients (100 normoalbuminuric patients, 103 microalbuminuric patients, and 93 macroalbuminuric patients) and 209 controls were enrolled in the present study. Polymorphisms of +45, -11391, and +276 of the ADIPOQ gene were detected using polymerase chain reaction restriction fragment length polymorphism. Serum adiponectin was measured using ELISA. Our results revealed that ADIPOQ +45 TG and GG genotypes and G allele were significantly associated with T2DM, micro/macroalbuminuria, and decreased serum adiponectin level. ADIPOQ -11391 AA genotype frequency was significantly increased in T2DM group. Moreover, GA and AA genotypes and A allele of ADIPOQ -11391 were significantly associated with susceptibility to macroalbuminuria despite increased serum adiponectin concentrations. While, ADIPOQ +276 TT genotype and T allele were protective factors regarding the susceptibility to T2DM and micro/macroalbuminuria, and they were significantly associated with increased adiponectin levels. We observed also that the decrease of the serum Adiponectin level was accompanied by an insulin resistance, albuminuria, as well as an increase of serum creatinine. We concluded that ADIPOQ +45; ADIPOQ -11391 gene polymorphisms are associated with T2DM and/or DN in Egyptian population. While, ADIPOQ +276 gene polymorphism is a protective factor regarding T2DM and/or DN susceptibility.
最近，有几份报告探讨了脂联素（ADIPOQ）基因多态性与脂联素血清水平异常、2型糖尿病（T2DM）和糖尿病肾病（DN）之间的关联；然而，结果并不一致。本研究旨在调查ADIPOQ基因多态性与T2DM和/或DN之间可能存在的关联，以及它们是否会影响埃及人群的血清脂联素水平。本研究纳入了296例T2DM患者（100例正常白蛋白尿患者、103例微量白蛋白尿患者和93例大量白蛋白尿患者）和209例对照。采用聚合酶链反应-限制性片段长度多态性检测ADIPOQ基因+45、-11391和+276位点的多态性。使用酶联免疫吸附测定法测量血清脂联素。我们的结果显示，ADIPOQ +45位点的TG和GG基因型以及G等位基因与T2DM、微量/大量白蛋白尿和血清脂联素水平降低显著相关。ADIPOQ -11391位点的AA基因型频率在T2DM组中显著增加。此外，尽管血清脂联素浓度升高，但ADIPOQ -11391位点的GA和AA基因型以及A等位基因与大量白蛋白尿的易感性显著相关。而ADIPOQ +276位点的TT基因型和T等位基因是T2DM和微量/大量白蛋白尿易感性的保护因素，并且它们与脂联素水平升高显著相关。我们还观察到血清脂联素水平降低伴随着胰岛素抵抗、蛋白尿以及血清肌酐升高。我们得出结论，ADIPOQ +45；ADIPOQ -11391基因多态性与埃及人群的T2DM和/或DN相关。而ADIPOQ +276基因多态性是T2DM和/或DN易感性的保护因素。
